Gall bladder perforation in response to chemotherapy in a patient with a histiocytic lymphoma.
Schaafsma
M R
MR
Peters
W G
WG
Tham
R T
RT
Alleman
M J
MJ
Willemze
R
R
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001201:Ascites / Q000209:etiology; D001646:Bile; D001761:Bleomycin / Q000627:therapeutic use; D002915:Chylous Ascites / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005705:Gallbladder Diseases / Q000209:etiology*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate